Table 1.
Characteristics of patients registered in the GENOM009 trial (clinicaltrials.gov NCT01102595)29.
| Characteristic | N = 102 N (%) |
|---|---|
| Included in outcome analyses | |
| No | 9 (8.82%) |
| Yes | 93 (91.2%) |
| Treatment arm | |
| A: temozolomide | 53 (52.0%) |
| B: temozolomide + bevacizumab | 49 (48.0%) |
| Age, yrs | |
| median (range) | 63 (36–79) |
| ≥50 years old | 97 (95.1%) |
| <50 years old | 5 (4.90%) |
| Sex | |
| Male | 60 (58.8%) |
| Female | 42 (41.2%) |
| ECOG PS | |
| 0–1 | 72 (71.3%) |
| >2 | 29 (28.7%) |
| MMSE score | |
| Unknown | 9 (8.82%) |
| <27 | 37 (36.3%) |
| >=27 | 56 (54.9%) |
| Neurologic impairment | |
| Unknown | 2 (1.96%) |
| No | 40 (39.2%) |
| Yes | 60 (58.8%) |
| Type of neurologic impairment | |
| None/Unknown | 41 (40.2%) |
| Cognitive | 5 (4.90%) |
| Convulsions | 2 (1.96%) |
| Language | 9 (8.82%) |
| More than one | 18 (17.6%) |
| Motor symptoms | 20 (19.6%) |
| Sensorial | 4 (3.92%) |
| Visual | 3 (2.94%) |
| Type of surgery | |
| Unknown | 2 (1.96%) |
| Biopsy | 83 (81.4%) |
| Partial resection | 17 (16.7%) |
| Number of lesions | |
| 1 | 78 (87.6%) |
| >1 | 11 (13.3%) |
| Tumor volume | |
| Median | 141.8 cm2 |
| Range | 16–528 cm2 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; MMSE, Mini-Mental State Examination.